TD Waterhouse Canada Inc. decreased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 34.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,721 shares of the company’s stock after selling 3,012 shares during the period. TD Waterhouse Canada Inc.’s holdings in IDEXX Laboratories were worth $3,076,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Harbour Investments Inc. boosted its holdings in shares of IDEXX Laboratories by 13.3% in the 4th quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock valued at $92,000 after purchasing an additional 16 shares in the last quarter. Pinnacle Associates Ltd. raised its holdings in shares of IDEXX Laboratories by 1.5% during the 4th quarter. Pinnacle Associates Ltd. now owns 1,227 shares of the company’s stock worth $830,000 after buying an additional 18 shares in the last quarter. Advisory Services Network LLC lifted its position in shares of IDEXX Laboratories by 2.5% during the 4th quarter. Advisory Services Network LLC now owns 752 shares of the company’s stock worth $509,000 after buying an additional 18 shares during the last quarter. Triad Wealth Partners LLC lifted its position in shares of IDEXX Laboratories by 3.1% during the 1st quarter. Triad Wealth Partners LLC now owns 600 shares of the company’s stock worth $337,000 after buying an additional 18 shares during the last quarter. Finally, KCM Investment Advisors LLC boosted its stake in IDEXX Laboratories by 5.3% in the fourth quarter. KCM Investment Advisors LLC now owns 377 shares of the company’s stock valued at $255,000 after buying an additional 19 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several research analysts have commented on IDXX shares. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, August 27th. Citigroup lifted their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. UBS Group increased their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Barclays cut their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Finally, Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $747.00.
IDEXX Laboratories Price Performance
Shares of NASDAQ:IDXX opened at $535.38 on Tuesday. The company has a market capitalization of $42.18 billion, a price-to-earnings ratio of 37.65, a P/E/G ratio of 2.86 and a beta of 1.54. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The business’s 50-day moving average is $558.25 and its 200-day moving average is $569.41. IDEXX Laboratories, Inc. has a 1 year low of $518.55 and a 1 year high of $769.98.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping the consensus estimate of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The firm’s revenue was up 9.7% on a year-over-year basis. During the same quarter last year, the firm posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities research analysts predict that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
Featured Stories
- Five stocks we like better than IDEXX Laboratories
- 3 Under-the-Radar Defense Stocks With Record Backlogs
- This Korea ETF Has Soared, But the Rally May Not Be Over
- Why Guidewire’s Post-Earnings Plunge May Not Last
- Ride-Share Reckoning: Tesla Drives Into Uber’s Lane
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
